MX2012013225A - Combinacion de yodo molecular y antraciclinas de uso humano para la prevencion y tratamiento de canceres quimiorresistentes captadores de yodo. - Google Patents

Combinacion de yodo molecular y antraciclinas de uso humano para la prevencion y tratamiento de canceres quimiorresistentes captadores de yodo.

Info

Publication number
MX2012013225A
MX2012013225A MX2012013225A MX2012013225A MX2012013225A MX 2012013225 A MX2012013225 A MX 2012013225A MX 2012013225 A MX2012013225 A MX 2012013225A MX 2012013225 A MX2012013225 A MX 2012013225A MX 2012013225 A MX2012013225 A MX 2012013225A
Authority
MX
Mexico
Prior art keywords
iodine
anthracyclines
combination
capturing
chemically
Prior art date
Application number
MX2012013225A
Other languages
English (en)
Other versions
MX348541B (es
Inventor
Carmen Yolanda Aceves Velasco
Rocío Brenda Anguiano Serrano
Original Assignee
Univ Nac Autónoma De México
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nac Autónoma De México filed Critical Univ Nac Autónoma De México
Priority to MX2012013225A priority Critical patent/MX348541B/es
Priority to PCT/MX2013/000139 priority patent/WO2014077668A1/es
Publication of MX2012013225A publication Critical patent/MX2012013225A/es
Publication of MX348541B publication Critical patent/MX348541B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica útil en a la prevención y tratamiento de cánceres quimiorresistentes captadores de yodo que comprende una composición de yodo molecular y antraciclinas de uso humano. La composición de yodo molecular es de administración oral o tópica y se administra en coadyuvancia con un tratamiento quimioterapéutico con antraciclinas, evitando que la célula cancerosa se vuelva resistente a las antraciclinas mediante la inhibición de la expresión de proteínas antiapoptóticas. La composición de yodo molecular se administra de forma continua previamente, secuencialmente, conjuntamente o simultáneamente al tratamiento quimioterapéutico con antraciclinas.
MX2012013225A 2012-11-14 2012-11-14 Combinación de yodo molecular y antraciclinas de uso humano para la prevención y tratamiento de cánceres quimiorresistentes captadores de yodo. MX348541B (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2012013225A MX348541B (es) 2012-11-14 2012-11-14 Combinación de yodo molecular y antraciclinas de uso humano para la prevención y tratamiento de cánceres quimiorresistentes captadores de yodo.
PCT/MX2013/000139 WO2014077668A1 (es) 2012-11-14 2013-11-14 Combinacion de yodo molecular y antraciclinas de uso humano para la prevencion y tratamiento de cánceres quimiorresistentes captadores de yodo

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012013225A MX348541B (es) 2012-11-14 2012-11-14 Combinación de yodo molecular y antraciclinas de uso humano para la prevención y tratamiento de cánceres quimiorresistentes captadores de yodo.

Publications (2)

Publication Number Publication Date
MX2012013225A true MX2012013225A (es) 2014-05-22
MX348541B MX348541B (es) 2017-06-01

Family

ID=50731498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013225A MX348541B (es) 2012-11-14 2012-11-14 Combinación de yodo molecular y antraciclinas de uso humano para la prevención y tratamiento de cánceres quimiorresistentes captadores de yodo.

Country Status (2)

Country Link
MX (1) MX348541B (es)
WO (1) WO2014077668A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462753A (en) * 1993-04-30 1995-10-31 Bhatta; Krishna M. Treatment of symptomatic benign prostatic hyperplasia
MX340005B (es) * 2010-04-23 2016-05-18 Univ Nac Autónoma De México Composicion de yodo molecular de uso humano para la prevencion y tratamiento de patologias prostaticas.

Also Published As

Publication number Publication date
MX348541B (es) 2017-06-01
WO2014077668A1 (es) 2014-05-22

Similar Documents

Publication Publication Date Title
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
HRP20181364T1 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
MX366899B (es) Nuevos compuestos.
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
MX2015008877A (es) Conjugados de disulfuro mixto de compuestos de tienopiridina y sus usos.
NZ739867A (en) Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
EP3181136A4 (en) Micelle containing epirubicin-complexed block copolymer and anti-cancer agent, and pharmaceutical composition containing said micelle applicable to treatment of cancer, resistant cancer or metastatic cancer
IN2015DN01328A (es)
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
EP2983684B8 (en) Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations
MX370957B (es) Compuesto de la familia de la avermectina o de la familia de la milbemicina para el tratamiento y/o la prevención de la dermatitis atópica.
MX348541B (es) Combinación de yodo molecular y antraciclinas de uso humano para la prevención y tratamiento de cánceres quimiorresistentes captadores de yodo.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.

Legal Events

Date Code Title Description
FG Grant or registration